InsiderTrades

Form 4 for PFE Pfizer

Accepted 2022-12-16 00:00:00 ET · period of report 2022-12-15 · accession 0001225208-22-012885 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2022-12-16 2022-12-16 PFE BOURLA ALBERT COB, CEO, Dir M - OptEx $27.25 +222.3K 411.9K +117% +$6.06M
DM 2022-12-16 2022-12-16 PFE BOURLA ALBERT COB, CEO, Dir M - OptEx $0.00 -431.1K 0 -100% $0
D 2022-12-16 2022-12-15 PFE BOURLA ALBERT COB, CEO, Dir A - Grant $53.61 +10 96.4K +0.0% +$536.10

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-12-16 M A 133,172 $30.17 322,734 D — — (F1) Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in Pfizer common stock price (20 trading day average ending on the exercise date (Election Price of $50.68)) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the fifth anniversary of grant.
2 Common Common Stock 2022-12-16 M A 89,156 $22.89 411,890 D — — (F2) Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in Pfizer common stock price (20 trading day average ending on the exercise date (Election Price of $50.68)) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the seventh anniversary of grant.
3 Derivative Stock Appreciation Rights 2022-12-16 M D 145,970 $0.00 0 D $22.89 · 2019-02-25 to 2023-02-25 145,970 Common Stock
4 Derivative Phantom Stock Units SSP 2022-12-15 A A 10 $53.61 96,391 D — · — to — 10 Common Stock (F3) Each unit represents one phantom share of common stock. (F4) These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.
5 Derivative Stock Appreciation Rights 2022-12-16 M D 285,161 $0.00 0 D $30.17 · 2021-02-22 to 2023-02-22 285,161 Common Stock